Difference between revisions of "Marotta LL, et al. J. Clin. Invest. (2011) cited as Ref 332 in DOI: 10.1038/s41392-020-0110-5 (Q9595)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 121, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English) | ||
| Property / title: The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English) / rank | |||
| + | Normal rank | ||
Revision as of 21:59, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Marotta LL, et al. J. Clin. Invest. (2011) cited as Ref 332 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Marotta LL
0 references
2011
0 references
J. Clin. Invest.
0 references
121
0 references
The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors (English)
0 references
